Abstract:Lan-Hui Li, 1 Hsiao-Wen Chiu, 2 Wei-Ting Wong, 2 Ko-Chieh Huang, 3 Tzu-Wen Lin, 3 Shui-Tein Chen, 3 Kuo-Feng Hua 2, 4 1 Department of Laboratory Medicine, Linsen, Chinese Medicine and Kunming Branch, Taipei City Hospital, Taipei, Taiwan; 2 Department of Biotechnology and Animal Science, National Ilan University, Yilan, Taiwan; 3 ALPS Biotech Co. Ltd, Taipei, Taiwan; 4 Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan Correspondence: Kuo-Feng Hua, Department of Biotechnology and Animal Science, National Ilan University, No. 1, Sec. 1, Shennong Road, Yilan, 260, Taiwan, Tel +886 3 931 7626, Fax +886 3 935 4794, Email Purpose: Coronavirus disease 2019 (COVID-19) poses a global health challenge with widespread transmission. Growing concerns about vaccine side effects, diminishing efficacy, and religious-based hesitancy highlight the need for alternative pharmacological approaches. Our study investigates the impact of the ethanol extract of Antrodia cinnamomea (AC), a native medicinal fungus from Taiwan, on COVID-19 in both in vitro and in vivo contexts. Methods: We measured the mRNA and protein levels of angiotensin-converting enzyme-2 (ACE2) in human lung cells using real-time reverse transcriptase-polymerase chain reaction and Western blotting, respectively. Additionally, we determined the enzymatic activity of ACE2 using the fluorogenic peptide substrate Mca-YVADAPK(Dnp)-OH. To assess the impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, we used SARS-CoV-2 pseudovirus infections in human embryonic kidney 293T cells expressing ACE2 to measure infection rates. Furthermore, we evaluated the in vivo efficacy of AC in mitigating COVID-19 by conducting experiments on hamsters infected with the Delta variant of SARS-CoV-2. Results: AC effectively decreased ACE2 mRNA and protein levels, a critical host receptor for the SARS-CoV-2 spike protein, in human lung cells. It also prevented the spike protein from binding to human lung cells. Dehydrosulphurenic acid, an isolate from AC, directly inhibited ACE2 protease activity with an inhibitory constant of 1.53 μM. In vitro experiments showed that both AC and dehydrosulphurenic acid significantly reduced the infection rate of SARS-CoV-2 pseudovirus. In hamsters infected with the Delta variant of SARS-CoV-2, oral administration of AC reduced body weight loss and improved lung injury. Notably, AC also inhibited IL-1β expression in both macrophages and the lung tissues of SARS-CoV-2-infected hamsters. Conclusion: AC shows potential as a nutraceutical for reducing the risk of SARS-CoV-2 infection by disrupting the interaction between ACE2 and the SARS-CoV-2 spike protein, and for preventing COVID-19-associated lung inflammation. Keywords: coronavirus disease 2019, angiotensin-converting enzyme-2, severe acute respiratory syndrome coronavirus 2, Antrodia cinnamomea , the intracellular sensor NACHT, LRR, PYD domain-containing protein 3 inflammasome, cytokine Graphical Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic since 2019, shares a common cell entry receptor known as angiotensin converting enzyme II (ACE2) with the SARS-CoV virus from 2002. 1 Research has shown that the initial step in viral infection involves the binding of the viral spike protein to ACE2. 2 Studies have revealed that individuals with hypertension, diabetes, or chronic obstructive lung disease exhibit significantly elevated levels of ACE2 expression in their lung tissues compared to those without these conditions. These findings offer a plausible explanation for the heightened severity of Coronavirus disease 2019 (COVID-19) in patients with these underlying health issues. 3 Additionally, in COVID-19 patients with heart failure, there was a notable increase in ACE2 expression within myocardial tissues, indicating that these individuals were more susceptible to SARS-CoV-2 infection in the heart, which could lead to severe complications. 4 These results suggest that reducing ACE2 expression might decrease an individual's susceptibility to SARS-CoV-2 infection and improve disease outcomes. However, it is essential to be mindful of potential side effects associated with downregulating ACE2. 5 Vaccination stands out as the primary strategy for managing the COVID-19 pandemic, garnering significant attention from researchers and the pharmaceutical industry in the quest to develop effective SARS-CoV-2 vaccines. 6 Nevertheless, issues such as vaccine side effects, diminishing v -Abstract Truncated-

Repurposing Astragalus Polysaccharide PG2 for Inhibiting ACE2 and SARS-CoV-2 Spike Syncytial Formation and Anti-Inflammatory Effects

1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection

EGCG, a Green Tea Catechin, as a Potential Therapeutic Agent for Symptomatic and Asymptomatic SARS-CoV-2 Infection

ACE2 Overexpressing Mesenchymal Stem Cells Alleviates COVID-19 Lung Injury by Inhibiting Pyroptosis.

Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2

Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19

Study on the potential of Sanghuangporus sanghuang and its components as COVID-19 spike protein receptor binding domain inhibitors

Cross-linking Peptide and Repurposed Drugs Inhibit Both Entry Pathways of SARS-CoV-2

Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations

The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion

Diosmetin-7-O-β-D-glucopyranoside from Pogostemonis Herba alleviated SARS-CoV-2-induced pneumonia by reshaping macrophage polarization and limiting viral replication

Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19

Screening of Botanical Drugs Against SARS-CoV-2 Entry

Oroxylin A is a Severe Acute Respiratory Syndrome Coronavirus 2‐spiked Pseudotyped Virus Blocker Obtained from Radix Scutellariae Using Angiotensin‐converting Enzyme II/cell Membrane Chromatography

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo

The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants

Antrodia cinnamomea May Interfere with the Interaction Between ACE2 and SARS-CoV-2 Spike Protein in vitro and Reduces Lung Inflammation in a Hamster Model of COVID-19

Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level

A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2)

Potential Therapeutic Approaches for the Early Entry of SARS-CoV-2 by Interrupting the Interaction Between the Spike Protein on SARS-CoV-2 and Angiotensin-Converting Enzyme 2 (ACE2)

Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets